Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAD in Fulminant Hepatic Failure
NCT00030225Phase 2Completed
- Sponsor
- Vital Therapies, Inc.
- Start
- Jan 2002
- Primary completion
- Feb 2003
- Modality
- Cell Therapies, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in fulminant hepatic failure (FHF) comparing ELAD with Standard of care (Control) (2 arms). Primary endpoint: Number of subjects reaching 30-Day survival. Started Jan 2002; status: completed.
02
Drugs
ELAD
03
Conditions
fulminant hepatic failure (FHF)
Beyond the preview
Go deeper on NCT00030225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030225.